CVS Health has agreed to pay 315 million dollars to settle allegations over opioid prescribing at its pharmacies, BioPharma Dive reported, closing another chapter of the pharmacy sector’s long legal reckoning with the epidemic.
The settlement resolves claims that CVS pharmacies filled opioid prescriptions that should have been flagged, the theory under which states and the federal government have pursued every large dispenser. For CVS the payment is material but bounded, and it follows the pattern of the opioid litigation endgame: the remaining cases settle at figures the chains can absorb, priced as a cost of having been the country’s default pharmacy during the prescribing era.
What does not settle is the compliance machinery the litigation built. Pharmacist verification duties, prescription monitoring checks and corresponding responsibility standards are now permanent operating costs, which is the settlement’s real long tail for the whole sector.